These
articles support and explain Dr. Plechner's studies. Select the article
you wish to read from the drop down list above. Some of the articles
are available in Adobe Acrobat PDF format (see link with respective
articles).
Treating Unrecognized Cortisol-Based Imbalances Offers Major Healing Benefits for Multiple Disorders
By Alfred J. Plechner, D.V.M.
Summary
During more than three decades of clinical practice involving many
thousands of cases, I have repeatedly identified an unrecognized
endocrine-immune disturbance as a major trigger of multiple problems in
canines and felines, including allergies, viral and other infectious
diseases, vaccination failures, inflammatory bowel, autoimmunity, and
cancer. In most cases, and for seemingly unrelated conditions, I have
restored health by correcting this disturbance with the same hormone
replacement program. The basis of the disturbance is genetic or
acquired impairment of cortisol. A domino effect ensues, disrupting the
hypothalamus-pituitary-adrenal axis. Hormones go awry. Estrogen, from
an apparent conversion of adrenal androgens, is overproduced. Thyroid
hormones are blocked. Immune function is compromised. I consistently
see this scenario in sick patients, including EVERY cancer patient I
treat.
The nature of cortisol imbalances The
typical pattern of imbalance involves low/excessively bound/defective
cortisol, elevated total estrogen, impaired thyroid function, and low
IgA, IgG, and IgM counts. Cortisol, a steroid hormone, is produced from
cholesterol through an enzymatic process in the middle layer of the
adrenal cortex—the zona fasciculata. Hormones secreted by the
hypothalamus and pituitary in the brain govern this activity.
Cortisol exerts an anti-inflammatory effect, a property that inspired
the development of clinically important cortisone (synthetic cortisol)
drugs more than fifty years ago. Much has been written about the
immunosuppressive properties of elevated cortisol and powerful
cortisone drugs but little attention given to its role as a central
regulating agent of the immune system. A normal level of cortisol
appears necessary for proper immune and inflammatory responses (see
Fig. 1). At a basal, physiologic level this hormone regulates molecular
mediators that turn on or turn off activity related to immunity and
inflammation (1). A deficiency leads to an unresponsive or destabilized
immune system, and increased vulnerability to stresses and infections
(2).
From
an endocrine standpoint, a lack of active cortisol disturbs the
hypothalamus-pituitary-adrenal feedback loop that governs cortisol
production. To increase a subnormal cortisol level, the pituitary steps
up adrenocorticotropic hormone (ACTH) secretion. This hormone
stimulates cortisol release.
However, when the adrenal cortex is unable to produce enough cortisol,
or for some reason the cortisol is excessively bound, or otherwise
inactive, and thus not recognized by the system, the pituitary
continues to produce ACTH in order to extract more cortisol.
One consistent consequence of this activity I have observed over the
years is a physiologically significant buildup of estrogen compounds
that have a further destabilizing effect. I have not seen this
phenomenon reported elsewhere. The increased estrogen may come from
ACTH-stimulated androgens, produced in the inner layer of the adrenal
cortex (zona reticularis), which convert in part to estrogens in
peripheral tissue (3) or from “interface” cortical tissue directly
secreting estrogen compounds (4, 5). I routinely measure elevated total
estrogen in all animals with the endocrine-immune disturbance—male and
female, intact or neutered—and thus the excess cannot be attributed to
ovarian activity. It is possible, however, that environmental
estrogenic compounds in industrial chemicals and in food (such as
soybeans) may contribute to increased estrogen as well.
Elevated estrogen disturbs the immune system in a number of ways,
including interference with the thymus gland (6), and has been
implicated in the initiation of autoimmune disorders (7). Moreover, too
much estrogen in the system may impair the synthesis of cortisol (8) as
well as bind active cortisol, thus further exacerbating a cortisol
abnormality. It is interesting to note that researchers have discovered
that phytoestrogens (estrogen compounds) in tofu and soy-based food
decrease cortisol production and increase androgens, some of which
convert to estrogen and raise the total estrogen level in the body (9).
When considered together, these factors add up to a vicious cycle of cortisol-estrogen interactions.
Medical science regards the hypothalamic-pituitary-adrenal axis, which
is part of the neuroendocrine system, as exerting a primary influence
on immune function (10), however researchers are still in the dark
about much of the countless details and interactions. My clinical
impression over the years has been that cortisol and estrogen have an
intimate relationship that effects the homeostasis of the
neuroendocrine system. If the relationship becomes disturbed, as it
obviously has in so many of the animals I test and treat, the immune
system becomes deregulated and disease protection is lost (Fig 2).
The combination of deficient cortisol and excess estrogen not only
destabilizes the immune system but also has considerable potential to
interfere with thyroid function and cause a slowdown of the metabolic
rate. Cortisol-estrogen imbalances can impact thyroid function by
binding thyroid hormones, decreasing transference of T4 to T3, and
impairing cellular uptake of T3 (11, 12, 13).
In the common endocrine-immune derangement I have identified there
appears to be no discernible involvement of the outer adrenal cortical
layer (zona glomerulosa), where aldosterone is manufactured. This
hormone helps maintain blood pressure and water and salt balance in the
body. In Addison’s Disease, a rare condition that affected President
Kennedy, there is a deficiency of both cortisol and aldosterone.
Causes of cortisol-based imbalances From my perspective, several primary factors appear to cause the cortisol deficit:
1. Genetics. For
decades, pets have been inbred to attain fashionable structural and
cosmetic effects. Many animals, and in particular dogs, are no longer
bred for hardiness, function, and work, such as hunting, herding,
tracking, and retrieving. This has caused a harmful narrowing of gene
pools along with major health problems.
Most popular dog breeds have been bred “almost exclusively to look good,” Time
reported in a 1994 cover article, and this “obsessive focus on
show-ring looks is crippling, sometimes fatally, America’s purebred
dogs” (14). Time noted that that there are more than 300 different
genetic disorders that may subject animals to enormous pain and
suffering. “The astonishing thing,” the magazine article reports, “is
that despite the scope of these diseases, veterinary researchers know
next to nothing about what causes them or how to cure them.” The
cortisol-based endocrine-immune mechanism I have identified may be
largely the result of such breeding practices. However, this and other
genetic problems are not limited to purebreds. Mating between animals
of different breeds has thoroughly spread genetic defects throughout
the dog and cat world, and today such defects are widely established
among all breeds—pure or mixed.
2. Toxicity.
Household pets are intimately exposed to many toxic compounds,
including lawn and garden compounds, rat poison, insect and snake
bites, anti-flea chemicals and other pesticides, anesthetic agents,
cleaning and disinfectant solutions, building and decorating materials,
and a multitude of chemical additives contained in highly processed
commercial diets. Sensitive animals may develop a variety of mild to
severe symptoms immediately following exposure, but less appreciated is
the potential to damage the adrenal glands, which I have seen occur in
many pets.
The adrenals are recognized as the most toxin-vulnerable organ in the
endocrine system. The majority of toxic damage has been observed in the
cortex, where steroidal hormones, including cortisol, are produced.
Indeed, the entire process of adrenal steroidogenesis “poses multiple
molecular targets” for disruption (15) and such disturbances can
fundamentally affect the whole body physiology and biochemistry (16).
3. Stress. Mounting
evidence in the field of human stress research indicates that
hypocortisolism is present in healthy individuals living under chronic
stress as well as in patients with stress-related bodily disorders.
This new evidence is challenging the widely held belief that stress
always results in an increased secretion of cortisol. A persistent lack
of cortisol may in fact be a frequent and widespread phenomenon,
researchers now say, promoting a greater risk for immune-related
disorders and other diseases (17).
Pets are subject to stress just as are humans. I have traced many cases
of endocrine-immune imbalances to household upheaval related to
divorce, transfer of ownership, constant hassling by children, the
addition of a new or incompatible animal in the house, boarding in
kennels, and even to excess exercise.
4. Poor nutrition. A
poor quality diet fed over a long period of time contributes to
systemic deficits, including lack of proper nutrition to endocrine
organs producing hormones. Moreover, the complex nature of processed
pet foods may not allow for the adequate absorption of essential
nutrients. Digestive enzyme deficiencies are commonplace, particularly
in aging animals.
Testing and treatment of imbalances In
the early 1970s I first developed my testing and treatment protocols
for cortisol-based imbalances and reported my observations in the
veterinary literature (18, 19, 20, 21). A key element in this approach
is a blood test that identifies specific imbalances, namely cortisol,
total estrogen, T3/T4 levels, and IgA, IgG, and IgM. Table 1 shows the
testing values I consider normal.
Originally I tested for T cell function. Testing showed that T cells,
just as B cells and their production of antibodies, were weakened by
hormonal imbalances. However, due to the expense of T cell testing to
clients this additional diagnostic procedure was discontinued.
In my analysis of test results, I place no great emphasis on the serum
cortisol value by itself because it does not clearly indicate how much
of the circulating cortisol is active, bound, or somehow defective, and
how much is actually working. I base my therapy decisions on assessing
and comparing the other hormonal and antibody measurements in the test.
Animals with a cortisol defect typically have elevated estrogen and low
antibody results, even if their cortisol reading is normal.
Standard tests usually measure only one estrogen compound: estradiol.
However, I test for total estrogen, which may include endogenous
compounds (estradiol, estrone, and estriol) from ovarian and adrenal
activity as well as estrogens from environmental and food sources (such
as soy). This provides a more accurate measurement for a potential
major disrupter of cortisol and thyroid activity. In animals, I have
found that even a slight upward variation of total estrogen out of the
normal range can be problematic.
The endocrine-immune test is based on a simple blood draw that is spun
down in a serum separator tube and refrigerated. It is shipped cold and
refrigerated at the lab until testing. If blood is not kept cold,
hormone and antibody results tend to be excessively and erroneously
high. Correct handling of the blood sample is critical.
The imbalances and their associated medical effects are typically
corrected with the long-term use of very low-dosage cortisone
preparations that serve as a cortisol replacement (Fig. 3). I use only
enough steroid replacement to eliminate the imbalances, and this in
turn usually resolves the medical effects. Depending on the individual
case, I use either pharmaceutical cortisone medications or a
bio-identical “natural” plant-based hydrocortisone obtained from a
compounding pharmacy. Starting daily oral dosages are as follows:
Medrol (methylprednisolone) or Prednisolone, 1 milligram per 10 pounds
of body weight, or Vetalog (triamcinolone acetonide), 125 milligrams
per 10 pounds; hydrocortisone, available through compounding
pharmacies, 1/2-milligram per 1 pound of body weight.
Most dogs, but very few cats, also require a T4 thyroid prescription,
such as Soloxine (levothyroxine sodium) at .10 milligrams per 10 pounds
of body weight twice daily. Thyroid supplementation serves a dual
purpose: to overcome any resistant thyroid impairment or binding effect
due to endogenous cortisol-estrogen imbalances and to guarantee proper
metabolizing/breakdown of the cortisol replacement medication within
twenty-four hours. I have found that with dogs, but not with cats, even
very low physiological dosages of steroid replacement have the
potential in some cases to build up in the body and cause side effects
unless T4 is taken as a daily accompaniment. For some species
variation, most cats do not require the extra thyroid. The exceptions
are cases involving FIP or frank hypothroidism.
Special attention must be given to the IgA level. IgA is the most
abundant antibody and is especially important in mucosal immunity. It
is an essential protective factor against infectious agents, allergens
and foreign proteins that enter the body via the mouth, nose and upper
respiratory tracts, the intestines, and reproductive tract (22). In
humans, IgA deficiency is recognized as the most frequent
immunodeficiency (23).
Clinical experience has taught me that IgA levels well below 60 mg/dl
reflect dysfunction in the intestinal mucosa. By this I mean probable
inflammation and malabsorption, including an inability to absorb
medication. Low IgA is often the overlooked basis for inflammatory
bowel disease. Animals with chronic bowel disorders (including food
allergies), respiratory and urinary tract disorders, and anaphylactic
and vaccine reactions invariably have abnormal IgA levels.
When IgA is moderately or substantially low I do not take a chance with
oral medication, and certainly not for critical patients with an
advanced, life-threatening disease. To ensure proper delivery of
medication, I use intravenous drips or an intramuscular injection. My
formula for IM injections is Vetalog (1 milligram per 10 pounds of body
weight) in combination with Depomedrol (methylprednisolone, 1 milligram
per 1 pound of body weight). In very critical cases I often double the
quantity of both compounds. The former medication is an
immediate-acting steroid, the latter a long-acting steroid that becomes
active after five to seven days. Once the IgA level returns to near
normal or normal, I switch patients to an oral steroid. However, some
patients who have had prolonged intestinal dysfunction because of low
IgA may require monthly IM injections on a long-term basis.
Two weeks after therapy begins (or three weeks, if using IM initially)
I retest to see how values have shifted. I adjust the program
accordingly. Once values normalize and clinical signs abate, I retest
on a six-month or annual basis.
Discussion About
two years ago I learned about the work of William Jefferies, M.D.,
professor emeritus of internal medicine at the University of Virginia.
For decades, Jefferies has championed the use of long-term physiologic
dosages of cortisone in human patients with “adrenocortical
deficiency,” that is, a mild deficiency of cortisol. Among other
conditions, he has reported significant improvement of allergies,
autoimmune disorders, and chronic fatigue, and he also suggests
potential benefits of this approach as part of a comprehensive cancer
treatment program. In his book, Safe Uses of Cortisol, he notes that
the persistent application of physiologic dosages of appropriate
steroids “might help patients with any type of malignancy by improving
their resistance to cancer” (24). In my experience, Jefferies’
suggestion is understated. In animals, I have found that cortisol
replacement therapy actually represents a primary healing modality,
even in advanced cancer cases. (25).
Defective/bound/deficient cortisol is grossly underdiagnosed in
veterinary medicine and appears to be so as well in human medicine
(26). Moreover, many doctors fear long-term cortisone usage at any
dosage because of the drug’s well-known side effects and its
immunosuppressant properties. This stigma has created a “unique
situation in which a normal hormone, one that is essential for life,
has developed such a bad reputation that many physicians and patients
are afraid to use it under any circumstances,” says Jefferies (27).
As Jefferies points out, it is not generally recognized that the
dangerous side effects of steroid therapy “occur only with certain
dosages and not with others. That there is a tremendous difference
between the effects of small ‘physiologic’ dosages and those of larger
‘pharmacologic’ dosages has not been emphasized” (28).
In recent years, a variety of successful applications of low-dosage
cortisone has been reported in the medical literature. They include
rheumatoid arthritis (29), polymyalgia rheumatica, a systematic
inflammatory disorder of the aged (30), and sepsis (31). Recognition of
the safety and benefits of long-term, low-dosage cortisone therapy thus
appears on the increase. Hopefully, in the process it will bring
attention to the centrality of cortisol’s immune regulating role.
Both Jefferies, in humans, and I, in animals, have found that
replacement with physiologic dosages of cortisone should not be stopped
upon initial remission of symptoms and signs. When medication is
stopped, the medical effects return. This is long-term therapy, usually
for a lifetime.
The method I have briefly described in this paper introduces a
potentially major healing tool for many of the most challenging
conditions confronted by veterinarians. The treatment funds a deficit,
realigns a hormonal derangement, resets the metabolism, and restores
coherence to an incoherent immune system. It controls disease and
supports the health of patients for as long as the program is
maintained. It can often save animals who might otherwise be destined
for euthanasia. Among other conditions, I have found this approach
effective for the following: chronic allergies; malabsorption and
digestive tract disorders; respiratory and urinary tract disorders,
including FLUTD; bacterial, fungal and viral infections, including
parvo, FeLV, FIP, and FIV; vaccination failures and complications;
autoimmunity; obesity; chronic kidney and liver diseases; Von
Willebrand’s Disease; epilepsy; aggression and other behavioral
problems; and cancer.
This approach can also be applied preventively to determine the
presence of imbalances in outwardly healthy animals. Used thusly it can
help avoid future suffering and premature death brought about by an
unsuspected adrenal defect with systemic repercussions.
Based on my experience with animals, and other veterinarians who use it
in their clinics, and the work of Jefferies and other researchers in
human medicine, I strongly believe that addressing cortisol-based
endocrine-immune imbalances offers significantly promising solutions
for disease prevention and control—for both people and pets.
-------------------------------------------------
Dr.
Plechner welcomes inquiries about his method from interested
veterinarians. He can be contacted at the California Animal Hospital,
1736 S. Sepulveda Blvd., Los Angeles CA 90025. Phone: 310-473-0969.
Email: . Web site: www.drplechner.com. His newest
book, Pets at Risk: From Allergies to Cancers, Remedies for an Unsuspected Epidemic, was recently published by NewSage Press (www. newsagepress.com).
References 1. Munck A., Naray-Fejes-Toth A. Glucocorticoid action. In: Endocrinology, Third edition, (Ed: DeGroot L). Philadelphia: W. B. Saunders Co, 1995: 1642-1654.
2. Jefferies WMcK. Safe Uses of Cortisol. Springfield: Charles C. Thomas Publisher, 1996: 128-148.
3. Parker, LN. Adrenal androgens. In: Endocrinology, Third edition, (Ed: DeGroot L). Philadelphia: W. B. Saunders Co, 1995: 1836-47.
4. Symington, T. Functional Pathology of the Human Adrenal Gland. Edinburgh: E & S Livingstone, 1969: 66-68.
5. Roberts E. The importance of being dehydroepiandrosterone sulfate. Biochem Pharmacol, 1999; 57: 329-46.
6. Cutolo M, Seriolo B, Villaggio B, Pizzorni C, Craviotto C, Sulli A.
Androgens and estrogens modulate the immune and inflammatory responses
in rheumatoid arthritis. Ann. N. Y. Acad. Sci., June 2002; 966: 131-42.
7. Lahita R. The connective tissue diseases and the overall influence of gender. Int J Fertil Menopausal Stud, 1996; 41 (2):156-165.
8. Gell JS, Oh J, Rainey WE, Carr BR. Effect of estradiol on DHEAS
production in the human adrenocortical cell line, H295R. J Soc Gynecol Investig, 1998; 5: 144-48.
9. Mesiano S, Katz S L, Lee J Y, Jaffe R B. Phytoestrogens alter
adrenocortical function: genistein and daidzein suppress glucocorticoid
and stimulate androgen production by cultured adrenal cortical cells. J Clin Endocrinol Metab, 1999; 84 (7): 2443-2448.
10. Cutolo M, et al. Altered neuroendocrine immune (NEI) networks in rheumatology. Ann. N.Y. Acad. Sci., June 2002; 966: xvii.
11. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med, 2001; 344 (23): 1743-1749.
12. Gross HA, Appleman MD, Nicoloff JT. Effect of biologically active steroids on thyroid function in man. J Clin Endocrinol Metab 1971; 33: 242-248.
13. Jefferies, op. cit., 160, 181.
14. Lemonick MD. A Terrible Beauty: An obsessive focus on show-ring
looks is crippling, sometimes fatally, America’s purebred dogs. Time, December 12, 1994; 65.
15. Harvey PW, Johnson I. Approaches to the assessment of toxicity data
with endpoints related to endocrine disruption. J Appl Toxicol, 2002; 22: 241-247.
16. Harvey PW. The Adrenal in Toxicology: Target Organ and Modulator of Toxicity. Bristol, PA: Taylor & Francis, 1996: 7.
17. Heim C, Ehlert U, Hellhammer DH. The potential role of
hypocortisolism in the pathophysiology of stress-related bodily
disorders. Pyschoneuroendocrinology, 2000; 25: 1-35.
18. Plechner A J, Shannon M. Canine immune complex diseases. Modern Veterinary Practice, November 1976: 917.
19. Plechner A J, Shannon M, Epstein A, Goldstein E, Howard EB. Endocrine-immune surveillance. Pulse, June-July, 1978.
20. Plechner A J. Theory of endocrine-immune surveillance. California Veterinarian, January 1979: 12.
21. Plechner A J. Preliminary observations on endocrine-associated
immunodeficiencies in dogs−a clinician explores the relationship of
immunodeficiencies to endocrinopathy. Modern Veterinary Practice, October 1979: 811.
22. Takahashi I, Kiyono H. Gut as the largest immunologic tissue. J Parenter Enteral Nutr, 1999; 23: Suppl S7-12.
23. Primary immunodeficiency diseases. Report of an International Union of Immunological Societies scientific group. Clin Exp Immunol, 1999; 118 (supplement 1): 1-17.
24. Jefferies, op. cit., 165.
25. Plechner AJ. An Innovative Cancer Therapy That Saves Animals. Can It Help Humans As Well? Townsend Letter for Doctors and Patients, GET REFERENCE.
26. Jefferies WMcK. Mild adrenocortical deficiency, chronic allergies,
autoimmune disorders and the chronic fatigue syndrome: A continuation
of the cortisone story. Med Hypotheses, 1994; 42: 183-189.
27. Jefferies, Safe Uses of Cortisol, 185.
28. Jefferies, ibid., 11.
29. Hickling P, Jacoby RK, Kirwan JR. Joint destruction after
glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol, 1998; 37: 930-936.
30. Cutolo M, Sulli A, Pizzorni C, et al. Cortisol,
dehydroepiandrosterone sulfate, and androstenedione levels in patients
with polymyalgia rheumatica during twelve months of glucocorticoid
therapy. Ann. N. Y. Acad. Sci., June 2002; 966: 91-96.
31. Klaitman V, Almog Y. Corticosteroids in sepsis: A new concept for an old drug. Isr Med Assoc J, 2003; 5 (1): 51-54.